Literature DB >> 2463216

Iron complexes and their reactivity in the bleomycin assay for radical-promoting loosely-bound iron.

J M Gutteridge1, Y Y Hou.   

Abstract

The sensitivity of the bleomycin assay for loosely-bound iron depends on the concentration of bleomycin and ascorbic acid and the pH of the reaction. The non-haem-iron proteins transferrin, conalbumin and ferritin release iron at an acid pH value, whereas the haem-iron proteins release iron more readily at an alkaline pH. In addition, haem proteins are liable to release iron when peroxides are present. Organic peroxides and hydrogen peroxide can be produced during the bleomycin reaction leading to iron release from haem proteins. However, this can be prevented from reacting with bleomycin by adding zinc ions to the reaction following addition of the sample. Iron already bound to bleomycin is not displaced by zinc whereas zinc bound to bleomycin is not displaced by iron allowing 'free' and 'released' iron to be discriminated.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2463216     DOI: 10.3109/10715768609088066

Source DB:  PubMed          Journal:  Free Radic Res Commun        ISSN: 8755-0199


  12 in total

1.  Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants.

Authors:  K Hirano; T Morinobu; H Kim; M Hiroi; R Ban; S Ogawa; H Ogihara; H Tamai; T Ogihara
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Bleomycin-detectable iron in knee-joint synovial fluid from arthritic patients and its relationship to the extracellular antioxidant activities of caeruloplasmin, transferrin and lactoferrin.

Authors:  J M Gutteridge
Journal:  Biochem J       Date:  1987-07-15       Impact factor: 3.857

3.  Haem oxygenase shows pro-oxidant activity in microsomal and cellular systems: implications for the release of low-molecular-mass iron.

Authors:  N J Lamb; G J Quinlan; S Mumby; T W Evans; J M Gutteridge
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

4.  Methylene blue plus light mediates 8-hydroxy 2'-deoxyguanosine formation in DNA preferentially over strand breakage.

Authors:  J E Schneider; S Price; L Maidt; J M Gutteridge; R A Floyd
Journal:  Nucleic Acids Res       Date:  1990-02-11       Impact factor: 16.971

5.  Cell based therapy reduces secondary damage and increases extent of microglial activation following cortical injury.

Authors:  Mary E Orczykowski; Samantha M Calderazzo; Eli Shobin; Monica A Pessina; Adrian L Oblak; Seth P Finklestein; Brian C Kramer; Farzad Mortazavi; Douglas L Rosene; Tara L Moore
Journal:  Brain Res       Date:  2019-04-15       Impact factor: 3.252

6.  Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.

Authors:  R A Zager
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions.

Authors:  C Smith; M J Mitchinson; O I Aruoma; B Halliwell
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

8.  Non-transferrin bound iron and neutropenia after cytotoxic chemotherapy.

Authors:  P Harrison; S S Marwah; R T Hughes; D Bareford
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

9.  Hyperferritinemia after adult allogeneic hematopoietic cell transplantation: quantification of iron burden by determining non-transferrin-bound iron.

Authors:  Tatsunori Goto; Katsuya Ikuta; Yoshihiro Inamoto; Sonoko Kamoshita; Emi Yokohata; Daisuke Koyama; Koichi Onodera; Aika Seto; Keisuke Watanabe; Nobuhiko Imahashi; Shokichi Tsukamoto; Yukiyasu Ozawa; Katsunori Sasaki; Masafumi Ito; Yutaka Kohgo; Koichi Miyamura
Journal:  Int J Hematol       Date:  2012-12-23       Impact factor: 2.490

10.  Effects of inorganic iron and myoglobin on in vitro proximal tubular lipid peroxidation and cytotoxicity.

Authors:  R A Zager; C A Foerder
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.